Cortexyme, Inc. (CRTX): Price and Financial Metrics
CRTX Price/Volume Stats
| Current price | $1.95 | 52-week high | $40.66 |
| Prev. close | $1.90 | 52-week low | $1.78 |
| Day low | $1.86 | Volume | 272,200 |
| Day high | $1.97 | Avg. volume | 620,672 |
| 50-day MA | $2.52 | Dividend yield | N/A |
| 200-day MA | $7.57 | Market Cap | 58.79M |
CRTX Stock Price Chart Interactive Chart >
Cortexyme, Inc. (CRTX) Company Bio
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases.
Latest CRTX News From Around the Web
Below are the latest news stories about CORTEXYME INC that investors may wish to consider to help them evaluate CRTX as an investment opportunity.
Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate NameSOUTH SAN FRANCISCO, Calif., August 01, 2022--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, provided an overview of its strategic growth plan in conjunction with its corporate name change today. The launch of Quince Therapeutics marks a strategic shift in focus as the company prioritizes the clinical development of its highly differentiated bone-targeting drug platform and lead precision |
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022SOUTH SAN FRANCISCO, Calif., July 27, 2022--Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics’ go-forward growth strategy and development pipeline plans. |
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588SOUTH SAN FRANCISCO, Calif., July 27, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company’s lysine gingipain inhibitor in development for the treatment of Alzheimer’s disease and indications with disease pathology associated with the keystone path |
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus InfectionsSOUTH SAN FRANCISCO, Calif., June 21, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after ora |
Cortexyme Appoints June Bray to its Board of DirectorsSOUTH SAN FRANCISCO, Calif., June 13, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board of Directors. |
CRTX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -84.92% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | 36.29% |
| 2020 | -50.52% |
| 2019 | N/A |
Loading social stream, please wait...